Your Roundup Cancer Case Is Not Over — What the Supreme Court Actually Ruled
You heard the news. The Supreme Court ruled against Roundup plaintiffs. You used Roundup for years — on your lawn, your garden, the grounds you maintained, the fields you worked — and then the diagnosis came. Cancer. And now you are sitting at your kitchen table at two in the morning, reading headlines that say the nation’s highest court just closed the door on people like you, and you are wondering whether it is even worth calling a lawyer.
It is. The door did not close. One door narrowed. Others are still open — and a federal judge in Massachusetts just said so on the record.
Here is what actually happened. The Supreme Court held that one specific type of claim — a state-law failure-to-warn claim that would require Monsanto to put a different cancer warning on the Roundup label than the one the EPA approved — is preempted by federal pesticide law. That is it. That is what the Court decided. It did not say Roundup is safe. It did not say Monsanto cannot be sued. It did not say glyphosate does not cause cancer. It said the label is controlled by the EPA, and state courts cannot order a different label.
What Judge Margaret Guzman did in the U.S. District Court for the District of Massachusetts was translate that ruling for the real world. She said the Supreme Court’s decision was — her words — “limited to claims based on Roundup’s labeling” and that it “left open other state law claims, such as the other types of product defect and consumer claims that are not based on warning theories.” She gave the plaintiffs in that case until August 28 to rewrite their complaint to pursue those surviving claims — design defect, consumer protection, negligent testing. The case is heading toward trial.
We are writing this page for one person: you. The person who used Roundup, got sick, and needs to know — clearly, honestly, without legal jargon — whether you still have a case, what it is worth, how long you have, and what to do next. That is what we do. We are Attorney911 — The Manginello Law Firm, PLLC, and we have spent more than 27 years in courtrooms fighting for people who were injured by products they were told were safe. Ralph Manginello has been trying cases since 1998. Lupe Peña spent years inside a national insurance-defense firm — the rooms where claims like yours are valued and minimized — before crossing to our side of the table. He conducts full consultations in Spanish without an interpreter.
What follows is the complete picture of Massachusetts Roundup litigation after the Supreme Court’s ruling: the law, the science, the evidence, the money, the defense playbook, and the roadmap. This is legal information, not legal advice. But it is the information you need right now, at two in the morning, from someone who knows this fight.
The Direct Answers: Can You Still Sue, What Claims Survive, What Your Case Is Worth
Can you still sue Monsanto for cancer caused by Roundup after the Supreme Court ruling? Yes. The Supreme Court’s decision in Monsanto Co. v. Durnell, No. 24-1068 (U.S. June 25, 2026), struck down one category of claim — label-based failure-to-warn — but a federal judge in Massachusetts has ruled that other claims survive. Your case is not dead. It needs to be built on the theories that preemption did not reach.
What claims survive? Design defect (the product’s formulation is inherently dangerous and a safer alternative existed), negligent design and testing (Monsanto failed to study its own product adequately and ignored internal signals of cancer risk), consumer protection and deceptive trade practices (Monsanto misled the public through marketing channels separate from the EPA-approved label), and breach of implied warranty of merchantability (the product was unfit for ordinary consumer use). Judge Guzman also suggested that a failure-to-warn theory based on warnings communicated through channels outside the product label — advertising, public statements, safety bulletins, direct communications — may survive preemption. Each of these is a different legal animal, and each requires different proof.
Why does Massachusetts law matter so much? Because the judge ruled that Massachusetts law governs these claims — not Missouri law, where some of the largest Roundup verdicts in the country were returned. Under Massachusetts law, punitive damages are not available in personal injury cases. The court cited the long-standing principle that, absent statutory authorization, punitive damages may not be awarded. The legislature has authorized punitive damages for wrongful death — but no similar provision exists for personal injury cases. This means the eye-popping numbers you may have read about from other states, where punitive damages drove verdicts to staggering heights, cannot happen here. Your case is worth what it is worth in compensatory damages — medical costs, lost income, pain and suffering, loss of consortium — and not a multiplied punitive award on top.
How long do you have? Massachusetts applies a three-year statute of limitations for tort actions. The clock generally starts when you discovered, or should have discovered, that your injury was connected to Roundup — not when you last used the product. In toxic tort cases, that discovery date is the critical question, because the latency between exposure and cancer diagnosis can span years or decades.
What is your case worth? Based on the analytical framework applied to Massachusetts Roundup cases — accounting for the punitive damages bar, the EPA’s contrary carcinogenicity classification, the narrowed liability theories, and the moderate federal venue — compensatory values in these cases can range from approximately $1.5 million at the low end to approximately $12 million at the high end, depending on the cancer subtype, treatment costs, prognosis, age, earning capacity, and exposure profile. These are analytical estimates, not predictions. Past results depend on the facts of each case and do not guarantee future outcomes.
Should you call a lawyer? If you used Roundup and were diagnosed with cancer — especially non-Hodgkin lymphoma, the cancer most frequently linked to glyphosate exposure in the scientific literature — the answer is yes, and the call is free. 1-888-ATTY-911. No fee unless we win your case.
Monsanto Co. v. Durnell: What the Supreme Court Held and What It Did Not Close
The Supreme Court decided Monsanto Co. v. Durnell on June 25, 2026, by a 7-2 vote. The holding was narrow, and understanding its precise boundaries is the difference between a case that survives and one that gets dismissed.
The Court held that 7 U.S.C. § 136v(b) — the preemption provision of the Federal Insecticide, Fungicide, and Rodenticide Act, known as FIFRA — expressly preempts state-law failure-to-warn claims that would require a pesticide label to bear a warning the EPA has not required. In plain English: FIFRA is the federal law that governs pesticides. It is administered by the EPA. Under FIFRA, no pesticide may be sold in the United States unless it is registered with the EPA, and the EPA must approve the product’s labeling before registration is granted. The label is not a suggestion — it is a federal document, reviewed and approved by a federal agency. The Supreme Court said that state courts cannot order Monsanto to put a different warning on that label, because doing so would conflict with the EPA’s federal authority over pesticide labeling.
“Except as provided by this subchapter, no person in any State may distribute or sell to any person any pesticide that is not registered under this subchapter.” — 7 U.S.C. § 136a(a); final printed labeling must be submitted to and accepted by EPA prior to registration, 40 CFR § 156.10(a)(6)(i).
That is the regulatory backbone. FIFRA makes the EPA the gatekeeper for what a pesticide label says. The Supreme Court said that state-law claims that demand a different label are preempted — meaning they are barred by federal law.
But here is what the Court did not do. It did not say that Monsanto is immune from all state-law claims related to Roundup. It did not say that FIFRA preempts design defect claims, or negligence claims, or consumer protection claims, or breach-of-warranty claims. It addressed one theory: failure-to-warn claims that would require a label different from what the EPA approved. Everything else was left for the lower courts to sort out.
And that is exactly what Judge Guzman is doing in the District of Massachusetts.
Judge Guzman’s Ruling: The Door That Stayed Open in Massachusetts
In Rubin v. Monsanto Co., No. 4:26-cv-40079 (D. Mass. July 29, 2026), Judge Margaret Guzman examined what Durnell actually preempted and what it left alive. Her interpretation is significant — and it is the reason Roundup cancer cases in Massachusetts federal court are still moving forward.
The plaintiffs in Rubin — a husband and wife who alleged that exposure to Monsanto’s Roundup weedkiller caused cancer — had sued under Massachusetts product liability law. After the Supreme Court decided Durnell, the question became: which of their claims survived?
Judge Guzman stated that Durnell was “limited to claims based on Roundup’s labeling” and that it “left open other state law claims, such as the other types of product defect and consumer claims that are not based on warning theories.” — Rubin v. Monsanto Co., No. 4:26-cv-40079 (D. Mass. July 29, 2026).
She also suggested that plaintiffs may be able to pursue a failure-to-warn theory based on allegations that Monsanto could have provided warnings outside the product label — through advertising, public statements, safety communications, or direct-to-consumer channels. This is a crucial distinction. The Supreme Court preempted claims that demand a different EPA-approved label. It did not address whether Monsanto had a duty to warn through other channels — channels that are not controlled by FIFRA’s labeling requirements.
Judge Guzman gave the plaintiffs until August 28 to amend their complaint to pursue these alternative theories. She cautioned — and this matters — that the amendment opportunity is not a guarantee of success. The amended claims must be precisely pleaded, adequately supported, and prepared to survive the defense motions that will certainly follow.
What does this mean for you? It means the legal landscape in Massachusetts is not frozen. It is actively developing. The District of Massachusetts has multiple pending Roundup cases. The Massachusetts Supreme Judicial Court is separately evaluating FIFRA preemption questions. The doctrine could shift before any trial date arrives. And the theories that Judge Guzman identified as surviving Durnell — design defect, consumer protection, negligent testing, non-label warnings, breach of warranty — are the foundation on which your case would need to be built.
Massachusetts Products Liability: How the Law Treats a Dangerous Product
Massachusetts approaches products liability through the implied warranty of merchantability — a legal doctrine that functions, in practice, nearly identically to the strict products liability principles in the Restatement (Second) of Torts § 402A that most states apply.
The Massachusetts Supreme Judicial Court has stated that liability under the implied warranty of merchantability is “congruent in nearly all respects with the principles expressed in Restatement (Second) of Torts § 402A.” — Commonwealth v. Johnson Insulation, 425 Mass. 650, 653–654 (1997), quoting Back v. Wickes Corp., 375 Mass. 633, 640 (1978); see also Vassallo v. Baxter Healthcare Corp., 428 Mass. 1, 21–22 (1998).
What this means in plain language: if a product is unreasonably dangerous — because of how it was designed, how it was manufactured, or because it failed to carry adequate warnings — the manufacturer can be held liable for the harm it causes, regardless of whether the manufacturer was “careful.” This is strict liability. You do not have to prove Monsanto was negligent. You have to prove the product was unreasonably dangerous and that it caused your injury.
In the Roundup context, this doctrine is the entry point. The question is whether Roundup’s glyphosate-based formulation is unreasonably dangerous — whether its risks outweigh its utility, whether a safer alternative design existed, and whether the product was unfit for the ordinary purposes for which a consumer would buy it.
The implied warranty of merchantability also provides a theory that may operate independently of FIFRA labeling preemption. A claim that a product was unfit for ordinary consumer use because of its carcinogenic properties does not necessarily depend on what the label said — it depends on what the product did. This is the architectural insight that keeps Roundup cases alive after Durnell: the warranty theory asks a different question than the warning theory. The warning theory asks whether the label should have said something different. The warranty theory asks whether the product itself was reasonably safe for its intended use. FIFRA controls the first question. It may not control the second.
Design Defect: The Feasible Alternative Design Requirement
Of the surviving theories that Judge Guzman identified, design defect may be the most demanding — and potentially the most powerful.
Under Massachusetts law, a plaintiff proves a design defect by showing that foreseeable dangers from the product could have been reduced or avoided if the manufacturer had used a reasonably feasible alternative design, and that the change would have reduced the risk of harm without costing too much or interfering with the product’s performance. — Evans v. Lorillard Tobacco Co., 465 Mass. 411, 428 (2013); Haglund v. Philip Morris, Inc., 446 Mass. 741, 747–748 (2006).
“PLF proves a design defect by showing that foreseeable or predictable dangers from the [product] could have been reduced or avoided by the manufacturer if it used a reasonably feasible alternative design, and that the [change] would have reduced the risk of harm.”
This is not a simple test. It requires proof of three things, each of which demands expert testimony:
First, that the danger was foreseeable. In the Roundup context, this means proving that Monsanto knew or should have known that glyphosate posed a cancer risk — that the scientific literature, internal research, or regulatory developments put the company on notice that its product could cause cancer. The International Agency for Research on Cancer (IARC), a branch of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” (Group 2A) in 2015. That classification is a foreseeable-danger marker. But the question is whether the danger was foreseeable before that — whether Monsanto’s own research, or the scientific literature available earlier, should have alerted the company to the risk.
Second, that a reasonably feasible alternative design existed. This is where the case lives or dies. The plaintiff must identify a specific alternative — a different formulation, a different active ingredient, a different delivery mechanism, a different concentration — that would have reduced the cancer risk without rendering the product ineffective or prohibitively expensive. This requires a formulation chemist or a product-design expert who can articulate the alternative and demonstrate its feasibility. A generalist who says “they should have made it safer” will not survive a Daubert challenge. The expert must say specifically what the alternative was, how it would have worked, what it would have cost, and why it would have reduced the risk.
Third, that the alternative would have reduced the risk without unduly compromising the product’s performance or making it too expensive. Roundup’s utility is weed control. An alternative that did not kill weeds effectively would not be a feasible alternative. An alternative that cost ten times as much might not be reasonably feasible. The test balances safety against utility — and the balance must be proven, not asserted.
What a generalist misses here is the specificity of the alternative-design requirement. Many lawyers file a design defect count that says nothing more than “the product was unreasonably dangerous and a safer alternative existed.” Under Massachusetts law, that is not enough. The Evans and Haglund standards demand a concretely identified alternative with expert support for its feasibility, cost, and risk-reduction potential. The amended complaint that Judge Guzman allowed must include this — or the design defect count will be dismissed.
The Punitive Damages Bar: Why Massachusetts Law Changes Everything
This is the single most important thing to understand about a Massachusetts Roundup case, and it is the thing that most people reading national news coverage will not grasp.
Massachusetts bars punitive damages in personal injury cases.
“Punitive damages are not favored in Massachusetts, and we have long followed the principle that, absent statutory authorization, punitive damages may not be awarded.” — Pine v. Rust, 535 N.E.2d 1247, 1249 (Mass. 1989).
The Massachusetts Legislature has authorized punitive damages in wrongful death cases — see Mass. Gen. Laws ch. 229, § 2 — but “no similar provision has been enacted for personal injury cases.” — Freeman v. World Airways, Inc., 596 F. Supp. 841, 846 (D. Mass. 1984); International Fidelity Ins. Co. v. Wilson, 387 Mass. 841, 856 n.20 (1983).
What this means: if you are a living plaintiff with a personal injury claim — cancer caused by Roundup — you cannot recover punitive damages in Massachusetts. Period. No matter how egregious Monsanto’s conduct was. No matter how much internal research was ignored. No matter how many public statements were misleading. The damage award is limited to compensation — the actual costs and losses you suffered — not punishment.
In other states, punitive damages have been the engine of massive Roundup verdicts. California permits exemplary damages upon a showing of malice, fraud, or oppression. Missouri permits punitive damages upon clear and convincing evidence that the defendant intentionally harmed the plaintiff without just cause or acted with a deliberate and flagrant disregard for the safety of others. These are different standards, and they have produced different results — but they share one thing: they allow juries to send a message with dollars that dwarfs the compensatory award.
Massachusetts does not allow that message. Your case is worth its compensatory value. That value can be substantial — cancer treatment costs, lost wages, diminished earning capacity, pain and suffering, loss of consortium, future medical care — but it is not multiplied by a punitive award.
Judge Guzman’s choice-of-law ruling applying Massachusetts law rather than Missouri law was, in practical terms, the most consequential ruling in the case. It is the difference between a case worth $12 million and a case worth $120 million. The plaintiffs argued for Missouri law — where Monsanto is headquartered and where some of the largest Roundup verdicts were returned — but the judge held that Massachusetts law governed because the exposure, the injury, and the plaintiffs’ connections to Massachusetts made it the proper forum’s law to apply.
For you, if you live in Massachusetts and were exposed to Roundup in Massachusetts, this is the reality. Your case has real value, but it is compensatory value. Understanding that from the start — not after you have read headlines about verdicts in other states and built expectations around them — is essential.
How Long You Have: The Three-Year Clock and the Discovery Rule
Massachusetts applies a three-year statute of limitations for tort actions.
“Except as otherwise provided, actions of tort, actions of contract to recover for personal injuries, and actions of replevin, shall be commenced only within three years next after the cause of action accrues.” — MGL c. 260, § 2A.
Three years. That is the outer boundary. But when does the clock start? This is the question that determines whether your case is alive or barred.
In most personal injury cases — a car crash, a slip-and-fall — the clock starts on the date of the injury. You know immediately that you were hurt. The connection between the event and the harm is obvious.
Toxic tort cases are different. The injury — cancer — may not appear for years or decades after the exposure. A person who used Roundup every weekend from 1995 to 2010 might not be diagnosed with non-Hodgkin lymphoma until 2023. If the clock started in 2010 — the date of last exposure — the case would be long barred. But Massachusetts, like most jurisdictions, applies a discovery rule: the clock starts when the plaintiff discovered, or in the exercise of reasonable diligence should have discovered, that she had been injured and that the injury was caused by the defendant’s product.
The discovery date is not always clear. It may be the date of diagnosis. It may be the date a doctor first mentioned a possible link between the cancer and chemical exposure. It may be the date the plaintiff first saw a news report connecting Roundup to cancer and made the connection to her own diagnosis. The defense will argue for the earliest possible date. The plaintiff will argue for the date of diagnosis or the date of actual discovery.
What this means for you: if you were diagnosed with cancer within the last three years, you are likely within the statute of limitations. If your diagnosis was more than three years ago, the question becomes when you first discovered, or should have discovered, the connection to Roundup. This is a fact-specific inquiry that depends on your specific circumstances — and it is one of the first things we examine when we evaluate a case.
Do not wait. The three-year clock is unforgiving, and the discovery rule is not a guarantee — it is an argument that must be proven. The day you call is the day that clock stops being your enemy.
Expert Testimony: The Daubert Battleground
If the legal theories are the architecture of your case, expert testimony is the foundation. Without admissible expert evidence on causation, your case cannot reach a jury — no matter how strong the legal theory.
In federal court — where the District of Massachusetts sits — expert testimony is governed by the Daubert standard, derived from the Supreme Court’s decision in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). Under Daubert, the judge serves as a gatekeeper, evaluating whether expert testimony is based on reliable methodology before allowing it to be presented to the jury. The court considers five nonexclusive factors: whether the methodology has been tested, whether it has been subjected to peer review, whether it has a known error rate, whether standards exist for its application, and whether it is generally accepted in the relevant scientific community.
Massachusetts state courts follow a related but not identical standard. Under Commonwealth v. Lanigan, 419 Mass. 15, 24–26 (1994), and the Massachusetts Guide to Evidence § 702 (2026), the proponent of expert testimony may establish reliability either by demonstrating general acceptance in the relevant scientific community or through a Daubert-style reliability analysis. General acceptance alone can be sufficient in Massachusetts state courts — a potentially lower bar than the federal Daubert standard. But in federal court, where the Rubin case and most Roundup cases are venued, the full Daubert analysis applies.
In a Roundup cancer case, you need experts in two categories:
General causation. A board-certified toxicologist or epidemiologist who can testify, to a reasonable degree of scientific certainty, that glyphosate is capable of causing cancer in humans — specifically, the type of cancer you were diagnosed with. This expert must present the scientific basis for that opinion: the mechanism of carcinogenicity (how glyphosate causes cellular damage that leads to cancer), the epidemiological studies that support the association, the dose-response relationship (how much exposure increases risk by how much), and the weight of the scientific literature. This expert will face cross-examination on the EPA’s classification, on studies that found no association, and on the methodological limitations of the studies the expert relies on. This is the single most important battle in the case.
Specific causation. A treating oncologist, hematologist, or forensic toxicologist who can testify that your specific cancer was caused by your specific exposure to Roundup. This requires a dose reconstruction — an estimate of how much glyphosate you were exposed to, over how many years, through what routes (skin absorption, inhalation, ingestion), and a methodology for connecting that dose to your cancer. This is harder than general causation because it requires individualized proof, not just a population-level association. The defense will argue that your cancer could have been caused by other factors — age, genetics, other chemical exposures, viral infections — and your expert must be prepared to rule those in or out with scientific rigor.
The Daubert motion is the defense’s most powerful weapon. If they can exclude your causation experts, your case is dismissed before it ever reaches a jury. This is why expert selection is not a box to check — it is the case. The experts must be board-certified, actively publishing in the field, experienced in courtroom testimony, and prepared for the specific challenges the defense will raise.
The EPA vs. IARC: The Causation Headwind You Must Understand
The EPA has classified glyphosate as “not likely to be carcinogenic to humans.” This is the regulatory position the defense will invoke at every stage — in motions, in Daubert briefs, in cross-examination, in closing argument. “The federal agency charged with evaluating pesticide safety,” the defense will say, “looked at glyphosate and said it does not cause cancer. The plaintiff’s experts say otherwise. Who are you going to believe — the EPA or a paid expert?”
This is a formidable argument, and pretending it does not exist would be malpractice. But it is not the whole story.
The International Agency for Research on Cancer (IARC), a specialized agency of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” (Group 2A) in 2015. IARC’s classification was based on a systematic review of the scientific literature, including studies showing associations between glyphosate exposure and non-Hodgkin lymphoma in humans, and evidence of carcinogenicity in laboratory animals. IARC’s process is widely respected in the scientific community and has been used as a reference by regulatory bodies worldwide.
So you have two authoritative bodies reaching different conclusions. The EPA says not likely carcinogenic. IARC says probably carcinogenic. How does a jury sort this out?
The answer is that the two organizations asked different questions and used different methodologies. IARC evaluates hazard — whether a substance is capable of causing cancer under any circumstances. The EPA evaluates risk — whether, at real-world exposure levels, a substance is likely to cause cancer. A substance can be a hazard (capable of causing cancer) but present a low risk at typical exposure levels — or the risk assessment can be contested because of disagreements about what constitutes a “typical” exposure level, especially for people who used Roundup heavily and repeatedly over many years.
Your case turns on this tension. Your experts must be prepared to explain why IARC’s classification, the epidemiological evidence, and the mechanistic data support a causation finding — and why the EPA’s classification does not foreclose that conclusion. This is not a simple task, and it is one of the reasons these cases are hard, slow, and expensive to litigate.
But hard is not the same as hopeless. The EPA’s classification is a regulatory determination, not a scientific proof of non-carcinogenicity. It is based on a review process that has been criticized — including by members of its own scientific advisory panel — for giving more weight to certain studies and less to others. Your experts can address these critiques. The EPA’s position is a headwind, not a wall.
Monsanto and Bayer: The Corporate Structure Behind the Defendant
Monsanto Co. is the manufacturer of Roundup. It designed the formulation, conducted the testing, submitted the regulatory filings, ran the marketing campaigns, and made the business decisions that put the product on shelves across Massachusetts and the nation. It is the named defendant in the Rubin case and in Roundup cancer cases across the country.
Bayer AG, the German pharmaceutical and agrochemical giant, acquired Monsanto in 2018. Monsanto now operates as a subsidiary of Bayer. The acquisition created the largest crop-chemical company in the world — and it transferred the legal liability for decades of Roundup litigation onto Bayer’s balance sheet.
Under Massachusetts law, a successor corporation is liable for a predecessor’s debts if the plaintiff proves by a preponderance that at least one of the following is true: (1) the successor expressly or impliedly assumed the predecessor’s obligations; (2) the transfer effected a merger or consolidation; (3) the successor merely continued the predecessor’s business; or (4) the transfer was a fraudulent effort to avoid the predecessor’s liabilities. — Mass. Super. Ct. Model Civil Jury Instructions, Successor Corporate Liability (Nov. 10, 2023); Milliken & Co. v. Duro Textiles, LLC, 451 Mass. 547, 557 (2008).
Because Monsanto still exists as a subsidiary, the successor liability question is not the primary path — Monsanto is still the named defendant and still has assets. But Bayer’s involvement matters for several reasons: it determines the depth of the pocket available to satisfy any judgment or settlement; it affects the strategic calculus of the defense, because Bayer is managing Roundup litigation globally; and it connects your case to the broader settlement framework that Bayer has proposed.
Bayer announced a proposed settlement framework for future Roundup claims. The framework is designed to provide compensation to people who develop cancer after using Roundup and who have not yet filed suit. The details of the framework — who qualifies, how claims are valued, what cancers are covered, what exposure thresholds apply — are complex and have been the subject of significant litigation and negotiation. The framework may provide an alternative resolution path for some plaintiffs, but individual case values within that framework depend on factors including exposure profile, cancer subtype, age, and prognosis.
What this means for you: the defendant in your case is not a small company that might disappear. It is one of the largest chemical corporations in the world, backed by a parent company with the resources to fight every case — and to settle them when the economics make sense. The question is not whether the defendant can pay. The question is whether your case is built strongly enough to force a fair resolution.
Evidence Preservation: What Exists, Who Holds It, How Fast It Dies
In a toxic tort case, the evidence that proves your exposure and your causation is not sitting in a file cabinet waiting to be requested. It is scattered across years of purchases, medical visits, employment records, and corporate documents — and some of it is disappearing right now.
Your medical records. Your cancer diagnosis, pathology reports, treatment history, and oncologist’s notes are the foundation of both your damages and your causation case. Under Massachusetts law, specifically 243 CMR 2.07(13), medical records for adult patients must be maintained for a minimum of seven years from the date of the last patient encounter. Note that the HIPAA Privacy Rule does not itself contain medical record retention requirements — retention is governed by state law, and Massachusetts sets that floor at seven years. But treating physicians retire, move, and die. Their recall of your specific case degrades over time. The pathology slides that confirmed your diagnosis are the single most important piece of medical evidence — they prove what you had, when it was identified, and its specific subtype. These must be obtained and preserved.
Roundup purchase receipts and product containers. This is the evidence that proves you actually used Roundup, how much you used, and over what period. Purchase receipts from hardware stores, garden centers, and online retailers. Product containers with labels that show the specific formulation and concentration. Usage logs if you maintained them for work. Witness statements from family members, coworkers, or neighbors who saw you use the product. This evidence is highly perishable. Consumers throw away receipts. Empty containers go into the recycling. Witness memory fades — not in months, but measurably over years. If you still have Roundup containers, old receipts, or photographs of the product in your shed or garage, preserve them now. Do not discard anything.
Monsanto’s internal scientific research and regulatory correspondence. These are the documents that can support design defect, negligent testing, and consumer deception claims. Internal research on glyphosate’s carcinogenicity. Communications with the EPA during the registration process. Internal discussions about IARC’s 2015 classification. Marketing materials and public statements about Roundup’s safety profile. Evidence of scientific ghostwriting — the practice of funding research and having it published under the names of academic scientists without disclosing Monsanto’s involvement. These documents are not going to be destroyed — corporate records are retained per regulatory and policy requirements — but they must be obtained through targeted discovery, and the defense will fight every request with privilege assertions and protective orders.
Expert witness reports. Your general causation expert’s report connecting glyphosate to cancer. Your specific causation expert’s report connecting your exposure to your diagnosis. A dose-reconstruction analysis estimating your cumulative exposure. These reports must be prepared, served, and defended against Daubert challenges — all within deadlines set by the court’s scheduling order. Missing an expert designation deadline can be case-dispositive.
Marketing materials and public statements. Monsanto’s advertising campaigns, safety assurances, public relations materials, and scientific publication records. These support the consumer protection and deceptive trade practices theories that Judge Guzman identified as surviving Durnell. If Monsanto told the public that Roundup was safe through channels other than the EPA-approved label, those statements are evidence — and they are not preempted by FIFRA, because they are not label-based claims.
The preservation letter — a formal demand that the defendant preserve all relevant documents, emails, internal studies, and communications — is the first step in freezing this evidence. In a Roundup case, the preservation letter goes to Monsanto’s legal department and covers a broad range of categories: all internal research on glyphosate carcinogenicity, all communications with regulatory bodies, all marketing and advertising materials, all documents referencing IARC’s classification, and all documents related to the product’s design and formulation. The day that letter goes out is the day the evidence clock starts working for you instead of against you. If documents are destroyed after that letter is on file, the law provides remedies — including adverse inference instructions that allow the jury to assume the destroyed evidence was as damaging as the plaintiff says it was.
What Your Case Is Worth: An Honest Assessment
Let us be direct about money, because you need to know the truth, and the truth is more useful than a fantasy.
The compensatory damage categories. Your case, if successful, can compensate you for:
Economic damages. Past medical treatment — surgery, chemotherapy, radiation, immunotherapy, hospital stays, diagnostic testing, prescription medications. Future medical treatment — ongoing therapy, surveillance monitoring, potential recurrence treatment, stem cell transplant if indicated. Lost wages during treatment and recovery. Diminished earning capacity if your ability to work has been permanently affected. The cost of a life-care plan if your prognosis involves long-term care needs or disability.
Non-economic damages. Physical pain and suffering — the experience of cancer treatment, the side effects of chemotherapy and radiation, the fear and anxiety of living with a cancer diagnosis. Emotional distress. Loss of enjoyment of life — the activities, travel, hobbies, and daily pleasures that cancer took from you. Loss of consortium — for your spouse, the loss of companionship, intimacy, and the shared life you built together.
The punitive damages bar. As we discussed above, punitive damages are not available in Massachusetts personal injury cases. This is the single largest factor distinguishing your case from Roundup cases in California and Missouri, where punitive damages have driven verdicts to levels that compensatory damages alone cannot reach. Your case is worth its compensatory value. Full stop.
The case value range. Based on the analytical framework for Massachusetts Roundup cases — accounting for the compensatory-only posture, the EPA’s contrary classification, the narrowed post-Durnell theories, and the District of Massachusetts venue — estimated compensatory values range from approximately $1.5 million at the low end to approximately $12 million at the high end. The low end reflects a case with modest treatment costs, a favorable prognosis, limited wage loss, and a weaker exposure profile. The high end reflects a case with extensive treatment costs, ongoing medical needs, significant wage loss or earning-capacity impairment, a strong exposure profile, and a cancer subtype with clear scientific linkage to glyphosate. Most cases will fall somewhere between these poles.
These are analytical estimates, not predictions. The actual value of your case depends on your specific medical profile, your specific exposure history, the strength of your expert evidence, the venue, the judge, the jury, and the strategic decisions made by both sides. Past results depend on the facts of each case and do not guarantee future outcomes.
The settlement framework. Bayer’s proposed settlement framework for future Roundup claims may provide an alternative path to resolution, but individual case values within the framework are not publicly standardized and depend on case-specific factors. The framework is one option — not the only option, and not necessarily the best option for every plaintiff. A case with strong liability evidence and compelling damages may be worth more in litigation than in the framework. A case with weaker causation evidence or a shorter exposure profile may benefit from the framework’s structure. This is a strategic decision that depends on the specifics of your case.
If you want to understand what toxic tort claims like this involve and how we evaluate them, the principles are the same: we build the medicine, we build the exposure, we build the corporate accountability, and we build the number — from the ground up, with evidence.
The Medicine: Cancer, Causation, and the Long Road Ahead
If you or your loved one was diagnosed with cancer after years of Roundup use, you already know the medical side of this story in a way no lawyer ever will. You lived it. What follows is not a lecture about your own experience — it is the framework for how that experience becomes evidence in a courtroom.
The cancer. Roundup litigation has focused primarily on non-Hodgkin lymphoma (NHL) and its subtypes — diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, and others. The scientific literature connecting glyphosate exposure to NHL is the most developed, though other cancers have been studied as well. If your diagnosis is NHL or a related lymphoma, the scientific pathway between exposure and disease is the most established. If your diagnosis is a different cancer, the causation proof is more challenging — but not necessarily impossible, depending on the emerging science.
The latency. Cancer does not appear overnight. The latency period — the time between first exposure and diagnosis — for NHL associated with chemical exposure can span years to decades. This is why the exposure history is so critical: not just whether you used Roundup, but when, how often, how much, and through what routes. A groundskeeper who mixed and sprayed Roundup five days a week for fifteen years has a different exposure profile than a homeowner who used it once a month on a small garden. Both may have legitimate claims, but the dose reconstruction — the scientific estimate of cumulative exposure — will be different, and the strength of the specific causation evidence will track that difference.
The diagnosis and treatment. The pathology report from your biopsy is the definitive document — it identifies the cancer subtype, the stage at diagnosis, and the cellular characteristics that drive treatment decisions. Your treatment records document the chemotherapy regimens, radiation courses, immunotherapy protocols, hospitalizations, surgeries, and follow-up monitoring. Your oncologist’s notes capture your response to treatment, your side effects, your remission status or recurrence, and your prognosis. Together, these records build both the damages case (what this cancer cost you) and the causation case (what specifically you had and when it appeared).
The proof problem. The defense will argue that your cancer was caused by something other than Roundup. Non-Hodgkin lymphoma has multiple known risk factors: age, immune system suppression, certain infections (including Epstein-Barr virus and H. pylori), family history, and other chemical exposures. The defense will point to these alternatives and demand that your experts rule them out. Your specific causation expert must be prepared to address each alternative — to explain why, in your specific case, the most likely cause was glyphosate exposure, not age or genetics or a virus. This is the hardest part of the case, and it is where weak expert testimony collapses under cross-examination.
The long road. Cancer is not a single event. It is a continuing condition. Even in remission, the fear of recurrence shapes every day. Follow-up appointments, surveillance scans, and the knowledge that the cancer might return — these are not abstract concepts. They are the lived reality that a damages presentation must capture. If your case goes to trial, the jury must understand not just what cancer cost you in the past, but what it will cost you in the future — the medical monitoring, the psychological burden, the relationships strained, the plans deferred. A life-care planner quantifies the future medical costs. A forensic economist translates them into present value. But the human cost — the cost that no spreadsheet captures — is what a jury is asked to weigh when it awards non-economic damages. In Massachusetts, without punitive damages, that human cost is the heart of the case.
The Defense Playbook: What Monsanto’s Lawyers Will Try
Monsanto is represented by some of the most experienced product-liability defense lawyers in the country. They have tried Roundup cases across multiple states. They know the science, the law, and the strategic landscape. Here are the plays they will run — and here is how each one is countered.
Play 1: The Preemption Motion. The defense will file a motion to dismiss or for summary judgment arguing that your claims are preempted by FIFRA under the Durnell decision. This is the first play in every post-Durnell Roundup case.
Counter: The amended complaint must be surgically precise. Design defect claims must not reference the label. Consumer protection claims must be based on marketing channels distinct from the EPA-approved label. Negligent testing claims must be independent of any labeling requirement. The complaint must track Judge Guzman’s ruling that Durnell was “limited to claims based on Roundup’s labeling” and that other claims survive. If the complaint bleeds into label-based territory, the defense will seize on it and the judge will dismiss. Precision is the weapon.
Play 2: The Daubert Challenge. The defense will file Daubert motions to exclude your general and specific causation experts, arguing that their methodology is unreliable, that their opinions are not based on generally accepted science, and that the EPA’s classification undermines their reliability.
Counter: Your experts must be board-certified, actively publishing, and prepared to defend their methodology on the stand. The general causation expert must present the full weight of the scientific literature — the IARC classification, the epidemiological studies, the mechanistic data — and explain why the EPA’s classification does not control the scientific question. The specific causation expert must present a rigorous dose reconstruction and a differential diagnosis that rules in glyphosate and rules out alternative causes with scientific reasoning, not hand-waving. The experts must be prepped on every study the defense will cite against them and prepared to explain the methodological differences.
Play 3: The EPA Deference Argument. The defense will argue at every opportunity that the EPA, the federal agency charged with evaluating pesticide safety, has determined that glyphosate is “not likely to be carcinogenic to humans,” and that the jury should defer to that determination.
Counter: The EPA’s classification is a regulatory determination, not a scientific proof. It is based on a review process that has been criticized by scientists, including members of the EPA’s own advisory panel. IARC, a respected international body, reached a different conclusion using a different methodology. The jury is not bound by the EPA’s regulatory classification — it is asked to weigh the scientific evidence, and the experts on both sides provide the basis for that weighing. The EPA’s position is evidence the defense can present, but it is not conclusive. Your expert must be prepared to explain, in terms a jury can understand, why two authoritative bodies reached different conclusions and why the scientific evidence supports your case.
Play 4: The Statute of Limitations Defense. The defense will argue that your claim is time-barred — that the three-year clock started earlier than you say it did, because you should have known about the connection between Roundup and cancer before your diagnosis date or before you actually filed.
Counter: The discovery rule is your answer, but it must be supported by specific facts. When did you first learn that Roundup might cause cancer? When were you diagnosed? When did a doctor or other source first connect your cancer to chemical exposure? The timeline must be documented — not just asserted. Medical records, communication records, and your own testimony establish the discovery date. The defense will look for any evidence that you were aware of the Roundup-cancer link before you claim to have discovered it — social media posts, internet search history, conversations with friends. This is why you must be precise and honest about when you knew.
Play 5: The Specific Causation Attack. The defense will argue that you cannot prove your specific cancer was caused by Roundup, as opposed to any of the other known risk factors for your cancer type.
Counter: Your specific causation expert must conduct a differential diagnosis — a systematic process of identifying the likely cause of your disease by considering all possible causes and ruling them in or out based on the evidence. This is a recognized methodology in medicine, and when done rigorously, it can survive Daubert. The expert must consider your age, family history, other chemical exposures, viral exposures, immune system status, and any other relevant risk factors — and explain why glyphosate exposure is the most probable cause in your specific case. The stronger your exposure profile (heavy, prolonged, direct contact with concentrated product), the stronger the specific causation argument.
Play 6: The Comparative Fault Argument. The defense may argue that you were partly at fault — you chose to use a chemical product, you did not wear protective equipment, you used more than the label recommended.
Counter: Massachusetts follows a modified comparative negligence rule with a 51% bar. Under MGL c. 231, § 85, contributory negligence does not bar recovery where the plaintiff’s negligence “was not greater than the total amount of negligence attributable to the person or persons against whom recovery is sought.” In plain English: if you are found to be 50% at fault or less, your recovery is reduced by your percentage of fault but not eliminated. If you are 51% or more at fault, you are barred. The defense will try to push your fault above 50%. The counter is that a consumer who uses a product as directed, in accordance with the manufacturer’s instructions and the EPA-approved label, is not negligent — especially when the manufacturer’s marketing assured the public that the product was safe. The fault, if any, lies with the company that designed, tested, marketed, and sold a product it knew or should have known was dangerous.
Play 7: The Quick Settlement Offer. The defense may make an early settlement offer designed to resolve the case cheaply before you understand its full value — especially before your expert reports are complete and your life-care plan is finished.
Counter: Never accept a settlement offer before your damages are fully developed. The full value of a cancer case cannot be known until the treatment is complete (or its course is clear), the prognosis is established, the earning-capacity impact is quantified, and the future medical needs are projected by a life-care planner. An early offer is almost always a fraction of the case’s real value. This is where Lupe Peña’s experience inside the insurance-defense industry becomes critical — he knows how claims are valued, how reserves are set, and how early offers are calibrated to capture plaintiffs who do not yet know what their case is worth.
How a Roundup Case Is Actually Built
This is the chronological walk — what happens, in what order, and why each step matters. Not a summary. The actual process, from the day you call to the day a jury is selected or a settlement is signed.
Week one: the intake and the preservation letter. The first thing that happens is the intake — a detailed interview where we learn your medical history, your Roundup exposure history, your work history, and the timeline of your diagnosis. We gather your medical records, your pathology reports, and any evidence of Roundup purchases or use you still have. The preservation letter goes out to Monsanto immediately — a formal demand that all relevant documents, emails, internal studies, and communications be preserved. That letter creates a legal obligation. If documents are destroyed after it is received, the consequences can include adverse inference instructions and sanctions.
Months one through three: medical records and exposure reconstruction. We obtain your complete medical file — every pathology report, treatment note, scan, and oncologist opinion. We begin the exposure reconstruction: when did you use Roundup, how often, how much, in what concentration, through what routes of exposure (mixing, spraying, skin contact, inhalation), and in what settings (residential, occupational, agricultural). We identify witnesses — family members, coworkers, neighbors — who can corroborate your exposure. We locate purchase records from hardware stores, garden centers, and online retailers. We photograph any remaining product containers.
Months three through six: expert selection and retention. This is the most consequential phase. We identify and retain the general causation expert — a board-certified toxicologist or epidemiologist who can testify that glyphosate causes cancer. We identify and retain the specific causation expert — a toxicologist, oncologist, or forensic pathologist who can testify that your cancer was caused by your specific exposure. We may retain a dose-reconstruction specialist, an industrial hygienist, and a life-care planner. Each expert must be vetted for credentials, publication history, testimony experience, and ability to withstand Daubert challenges. The wrong expert sinks the case. The right expert is the case.
Months six through twelve: discovery. Written discovery — interrogatories, requests for production, requests for admission — goes to Monsanto. We demand internal research files, EPA correspondence, communications about IARC’s classification, marketing materials, public statements, scientific publication records, and any evidence of ghostwriting or third-party influence on the scientific literature. The defense will object, assert privilege, and produce documents with heavy redactions. We litigate each objection. Depositions follow — of Monsanto’s corporate representatives, their scientists, their regulatory affairs personnel, and their marketing executives. The depositions are where the case is won or lost, because they lock the defense into positions under oath that cannot be retreated from at trial.
Months twelve through eighteen: Daubert motions and summary judgment. The defense will file Daubert motions to exclude your experts. We respond with briefing that demonstrates the reliability of each expert’s methodology, the scientific basis for their opinions, and their qualifications. The court holds a Daubert hearing — a mini-trial on the admissibility of expert testimony — where each expert is questioned about their methodology. If the experts survive, the defense will file summary judgment motions arguing that, even with admissible expert testimony, the evidence is insufficient to prove causation. We respond with the full record — the medical evidence, the exposure reconstruction, the expert reports, and the discovery documents.
Month eighteen through trial: trial preparation. If the case survives dispositive motions — and many do not — we prepare for trial. Witness preparation, exhibit development, jury instructions, voir dire strategy, opening statement, and the sequencing of evidence. In the District of Massachusetts, the jury pool is drawn from a well-educated, diverse population that tends to be analytical on scientific evidence — which cuts both ways. Jurors may grasp complex carcinogenicity evidence more readily than jurors in other venues, but they will also demand rigorous proof and will not be swayed by emotion alone. Voir dire must probe attitudes toward federal regulatory deference, chemical safety, and corporate scientific transparency.
The trial. If the case reaches trial — and the judge cautioned that the January trial date is not guaranteed — the trial itself will likely last two to four weeks. The plaintiff presents first: the exposure evidence, the medical evidence, the general causation expert, the specific causation expert, the life-care planner, and the economist. The defense presents its case: its own experts challenging causation, the EPA classification, and alternative causation theories. Closing arguments. Jury deliberation. Verdict.
This is the real shape of a Roundup cancer case. It is not fast. It is not easy. It is not guaranteed. But it is a path — and it is a path that remains open in Massachusetts after the Supreme Court’s ruling.
Your First Steps: What to Do Right Now
First: get your medical treatment. Nothing in this page is more important than your health. If you are in active treatment, your treatment comes first. Your medical records are being created right now — every appointment, every scan, every oncologist note is evidence that will build your case. Follow your doctor’s instructions. Keep every document.
Second: document your Roundup exposure. Write down everything you can remember about your Roundup use — when you started, when you stopped, how often you used it, how much you used, where you bought it, what you used it for, whether you mixed concentrate or used ready-to-use formulations, whether you wore gloves or protective equipment, whether you sprayed it, pumped it, or wiped it. Photograph any Roundup containers you still have — the label, the formulation, the concentration. Save any receipts. Identify anyone who saw you use Roundup — family, friends, coworkers, neighbors — and write down their names and contact information.
Third: do not sign anything from Monsanto, Bayer, or any insurance company. If you receive a letter, a phone call, or a visit from anyone representing Monsanto or Bayer or their insurers, do not speak with them. Do not sign any document. Do not provide a recorded statement. Do not accept any payment. Everything you say can and will be used against you. Everything you sign may include a release that extinguishes your claim.
Fourth: do not post about your case on social media. The defense monitors social media. Posts about your health, your activities, your emotional state, and your Roundup use can be taken out of context and used to undermine your case. If you have already posted about your cancer diagnosis or Roundup use, do not delete those posts — deletion can be treated as evidence destruction — but stop posting about it.
Fifth: call us. 1-888-ATTY-911. The call is free. The consultation is free. We will listen to your story, evaluate your exposure and your medical history, and give you an honest assessment of whether you have a case and what it may be worth. If we are not the right fit for you, we will tell you. If we are, we will explain exactly what happens next — step by step, no pressure, no sales pitch. We do not get paid unless we win your case. That is not a slogan — it is the fee agreement, in writing, 33.33% before trial, 40% if the case goes to trial.
Why Our Firm
Attorney911 — The Manginello Law Firm, PLLC has been fighting for injured people since 2001. We have recovered more than $50 million for our clients. We handle toxic tort claims, wrongful death cases, catastrophic injury cases, and product liability cases — the fights where the stakes are highest and the defendants are largest.
Ralph P. Manginello has been licensed since November 6, 1998 — 27+ years of trial practice. He is admitted to the U.S. District Court for the Southern District of Texas, which means he is federal-court admitted and familiar with the federal procedures that govern Roundup cases in the District of Massachusetts. He was a journalist before he was a lawyer, which means he knows how to take a complex story and make it clear to a jury. He has tried cases against some of the largest defendants in the country, and he does not settle for less than a case is worth.
Lupe Peña is the advantage most firms cannot offer. He spent years as an insurance-defense attorney at a national defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims like yours. He knows how claims are valued using industry software, how reserves are set, how IME doctors are selected, and how surveillance and social-media monitoring are deployed against plaintiffs. He now uses that knowledge for injured people. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. Hablamos Español.
We are a contingency-fee firm. That means you pay nothing out of pocket. We front the costs of litigation — the expert fees, the filing fees, the deposition costs, the document production expenses. If we win, our fee is 33.33% of the recovery before trial and 40% if the case goes to trial. If we do not win, you owe us nothing for our time. That is the arrangement, in writing, before any work begins.
We are not counsel on the Rubin case or any other case discussed on this page. We were not retained by anyone involved in that litigation. We have taken no action on that case. What we are is a firm with the knowledge, the experience, and the resources to evaluate your Roundup cancer claim, to tell you honestly whether you have a case, and — if you do — to build it from the ground up. The education on this page, the law, the evidence, the medicine, the defense playbook — this is what we bring. The decision to call is yours.
Past results depend on the facts of each case and do not guarantee future outcomes.
Frequently Asked Questions
Can I still file a Roundup cancer lawsuit after the Supreme Court’s Durnell ruling?
Yes. The Supreme Court’s decision in Monsanto Co. v. Durnell preempted only label-based failure-to-warn claims — claims that would require Monsanto to put a cancer warning on the Roundup label different from what the EPA approved. Other claims — design defect, negligent testing, consumer protection, breach of warranty, and possibly non-label failure-to-warn — remain viable. A federal judge in the District of Massachusetts has confirmed this on the record, giving plaintiffs leave to amend their complaint to pursue these alternative theories.
What types of cancer are linked to Roundup?
Roundup litigation has focused primarily on non-Hodgkin lymphoma (NHL) and its subtypes, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. The scientific literature connecting glyphosate exposure to NHL is the most developed. Other cancers have been studied but the causation evidence is less established. If you were diagnosed with NHL or a related lymphoma after prolonged Roundup use, the scientific pathway is strongest. If your diagnosis is a different cancer type, call us — the specific facts of your case determine whether a viable claim exists.
How long do I have to file a Roundup cancer lawsuit in Massachusetts?
Massachusetts applies a three-year statute of limitations for tort actions, under MGL c. 260, § 2A. The clock generally starts when you discovered, or in the exercise of reasonable diligence should have discovered, that your injury was caused by the defendant’s product. For toxic tort cases, this is typically the date of cancer diagnosis or the date you first learned of a possible connection between your cancer and Roundup exposure. If your diagnosis was within the last three years, you are likely within the limitations period. If it was longer ago, the discovery date becomes a critical question that requires legal analysis.
Why can’t I get punitive damages in Massachusetts?
Massachusetts law bars punitive damages in personal injury cases absent statutory authorization. The legislature has authorized punitive damages only for wrongful death — no similar provision exists for personal injury claims. This means that no matter how egregious Monsanto’s conduct was — no matter how much internal research was ignored or how misleading the public statements were — a Massachusetts personal injury jury cannot award punitive damages. Your recovery is limited to compensatory damages: medical costs, lost income, pain and suffering, and related losses. This is the single largest difference between Massachusetts Roundup cases and cases in states like California and Missouri, where punitive damages are available.
What if I used Roundup years ago but was just diagnosed with cancer?
The latency period between chemical exposure and cancer diagnosis can span years or decades. Massachusetts applies a discovery rule that generally starts the statute-of-limitations clock when you discovered, or should have discovered, the connection between your injury and the product — not when you last used the product. If you were recently diagnosed and only recently learned that Roundup may have caused your cancer, you may still be within the three-year limitations period even if your Roundup use ended years ago. The specific facts of your case determine the analysis — call us to discuss your timeline.
Do I need to have the Roundup container or receipts to file a claim?
Physical evidence — product containers, purchase receipts, usage logs — strengthens a case significantly but is not always essential. Product identification and exposure proof can be established through witness testimony, employment records, purchase histories reconstructed from retailer records, and circumstantial evidence of Roundup use. However, if you still have any Roundup containers, receipts, or photographs of the product, preserve them. Do not discard anything. The more specific your exposure evidence, the stronger your specific causation case.
What if I was partly at fault for using Roundup without protective equipment?
Massachusetts follows a modified comparative negligence rule with a 51% bar. If you are found to be 50% or less at fault, your recovery is reduced by your percentage of fault but not eliminated. If you are 51% or more at fault, you are barred from recovery. The defense will try to assign you fault for not wearing protective equipment or for using more product than the label recommended. The counter is that a consumer who uses a product as directed, in accordance with the manufacturer’s instructions and marketing assurances, is not negligent — the manufacturer is responsible for designing and selling a safe product.
How much does it cost to hire a lawyer for a Roundup cancer case?
Nothing out of pocket. We work on contingency — 33.33% of the recovery before trial, 40% if the case goes to trial. We front the costs of litigation, including expert fees, filing fees, and deposition expenses. If we do not win your case, you owe us nothing for our time. The consultation is free. The call is free. 1-888-ATTY-911.
How long does a Roundup cancer case take?
These cases are complex and typically take 18 to 36 months from filing to resolution, assuming the case is not dismissed at the Daubert or summary judgment stage. The timeline depends on the court’s docket, the complexity of the discovery, the number of expert witnesses, and whether the case settles or goes to trial. Some cases may resolve more quickly through the settlement framework. Others may take longer if they proceed through full discovery and trial preparation. We will give you an honest timeline estimate based on the specifics of your case.
What if my loved one died from cancer caused by Roundup?
If your loved one died from cancer that you believe was caused by Roundup exposure, a wrongful death claim may be available. Massachusetts has authorized punitive damages in wrongful death cases under Mass. Gen. Laws ch. 229, § 2 — making wrongful death claims potentially more valuable than personal injury claims under Massachusetts law. A personal representative must be appointed to bring the claim on behalf of the estate and the surviving family members. The statute of limitations and the procedural requirements are specific — contact us as soon as possible to discuss your situation.
Will my case go to trial?
Most Roundup cases settle before trial, but not all. Some cases are dismissed at the motion-to-dismiss or summary judgment stage. Some survive pretrial motions and proceed to trial. Whether your specific case goes to trial depends on the strength of your evidence, the willingness of the defendant to make a fair settlement offer, the court’s rulings on preemption and Daubert motions, and your own preference. We prepare every case as if it is going to trial — because that is how you get the best settlement, and because if trial is necessary, we are ready.
Is the Bayer settlement framework my only option?
No. The settlement framework proposed by Bayer is one potential resolution path, but it is not the only option. You have the right to file a lawsuit and pursue your case through litigation. The framework may offer a faster resolution for some plaintiffs, but individual case values within the framework depend on case-specific factors and may be lower than what you could recover through litigation. Whether the framework or litigation is the better path depends on the strength of your case, your timeline, and your willingness to endure the litigation process. We evaluate both options and advise you honestly.
Can I still sue if I live in Massachusetts but used Roundup in another state?
Possibly. The choice-of-law ruling in the Rubin case applied Massachusetts law because of the plaintiffs’ connections to Massachusetts. If you live in Massachusetts, were diagnosed in Massachusetts, and have significant connections to the state, Massachusetts law may govern your claim even if some or all of your Roundup exposure occurred elsewhere. The choice-of-law analysis is fact-specific and depends on the relative connections of the parties and the conduct to each state. This is one of the first issues we evaluate.
The Supreme Court did not close your door. A federal judge in Massachusetts confirmed that the door is still open — on design defect, on consumer protection, on negligent testing, on breach of warranty. The path is harder than it was before Durnell. The punitive damages are gone. The EPA’s classification is a headwind. The expert battle is the fight of the case. But the path exists, and people are walking it right now, in the same federal courthouse where your case could be filed.
If you used Roundup and cancer followed, call us. 1-888-ATTY-911. Free consultation. No fee unless we win your case. Hablamos Español. We will listen to your story, evaluate your claim honestly, and tell you — plainly — whether you have a case and what we can do about it. That call is the first step. Everything in this page is the foundation. The next move is yours.